Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 203

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 3
Chunk 203
---
, filed with the SEC on February
6, 2025, and accompanying base prospectus, pursuant to Rule 424(b)(5) promulgated under the Securities Act of 1933, as amended (the “Securities
Act”).

In a concurrent private placement, the Company
also issued to the February 2025 Purchasers unregistered warrants (the “February 2025 Warrants”) to purchase up to an aggregate
of 300,700 shares of common stock at an exercise price of $2.95 per share. The February 2025 Warrants are exercisable upon issuance and
expire twenty-four months from the date of issuance.

Any holder will not have the right to exercise
any portion of the February 2025 Warrants if the holder (together with its affiliates) would beneficially own more than 4.99% (or, upon
the election of the holder, 9.99%) of the number of shares of the common stock outstanding immediately after giving effect to the exercise,
as such percentage ownership is determined in accordance with the terms of the warrants. However, any holder may increase or decrease
such percentage, provided that any increase will not be effective until the 61st day after such election.

The exercise price of the February 2025 Warrants
is subject to customary adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications
or similar events affecting the Common Stock and also upon any distributions of assets, including cash, stock or other property to the
stockholders of the Company.

The issuance of the February 2025 Warrants pursuant
to the February 2025 Securities Purchase Agreement and the issuance of the February 2025 Placement Agent Warrants, as defined below, and
the shares of common stock issuable thereunder, were made pursuant to the exemption from the registration requirements under the Securities
Act of 1933, as amended (the “Securities Act”), available to the Company under Section 4(a)(2) promulgated thereunder and
Rule 506 of Regulation D promulgated under the Securities Act due to the fact that the offering of the February 2025 Warrants and the
February 2025 Placement Agent Warrants thereunder did not involve a public offering of securities.

The February 2025 Securities Purchase Agreement
contained customary representations and warranties. The offering closed on February 6, 2025.

37

Pursuant to an engagement letter agreement between